CD-NP (chimeric natriuretic peptide) is a novel natriuretic peptide developed by the Mayo Clinic as a potential treatment for heart failure. CD-NP is created by the fusion of the 15 amino acid C-terminus of DNP with the full CNP structure both peptide which are endogenous to humans. This peptide chimera is a dual activator of the natriuretic peptide receptors NPR-A and NPR-B and therefore exhibits the natriuretic and diuretic properties of DNP, as well as the antiproliferative and antifibrotic properties of CNP.